REG-Arix Bioscience PLC Board Change

Arix BioscienceAnnouncement

27/09/2023 07:15

============

   Arix Bioscience PLC (ARIX)
   Board Change

   27-Sep-2023 / 07:00 GMT/BST

   ══════════════════════════════════════════════════════════════════════════

                                        

                                        

                                        

   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU
                      MARKET ABUSE REGULATION NO.596/2014

                                        

                              Arix Bioscience plc

                                        

                                  Board Change

    

   LONDON, 27 September 2023: Arix  Bioscience plc (“Arix” or the  “Company”)
   (LSE: ARIX), a transatlantic venture capital company focused on  investing
   in breakthrough biotechnology companies, today announces that Robert Lyne,
   Chief Executive Officer  has decided  to step  down from  his position  to
   pursue a new opportunity and will leave the company by the end of 2023.

    

   Peregrine Moncreiffe, Chairman of Arix, stated:

    

   “Robert has been a pivotal part of Arix’s journey and its founding purpose
   of bringing breakthrough  advances in biotechnology  to patients who  need
   them while delivering  significant returns to  shareholders. He  navigated
   the company following  a period of  corporate governance uncertainty,  and
   through the Covid pandemic and  subsequent market volatility, deploying  a
   dual approach of conserving cash while enhancing value in the portfolio by
   selecting highly prospective new investments. This strategy has  preserved
   shareholder value  during a  period of  sustained market  uncertainty.  We
   thank Robert for his significant contributions to Arix over the years  and
   wish him well in the future.

    

   “Going forward, the Board’s primary focus will be to maximise  shareholder
   returns and  unlock the  value in  the Arix  portfolio. Consequently,  the
   Board  will  determine  appropriate  Board  and  management   arrangements
   following the  outcome of  the strategic  review and  update  shareholders
   accordingly. The Board will maintain its decision-making  responsibilities
   on all investment decisions.” 

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 1 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    2 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience plc is a transatlantic venture capital company focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  BOA
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   274074
   EQS News ID:    1735077


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1735077&application_name=news&site_id=refinitiv

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1735077&site_id=refinitiv&application_name=news


============